SRRK - Scholar Rock Holding Corporation
| Previous Close | 18.01 |
| Open | 17.92 |
| Bid | 18.11 x 800 |
| Ask | 18.34 x 1200 |
| Day's Range | 17.92 - 18.40 |
| 52 Week Range | 13.09 - 30.00 |
| Volume | 25,815 |
| Avg. Volume | 112,116 |
| Market Cap | 482.435M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.15 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.67 |
- GlobeNewswire•14 days ago
Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
CAMBRIDGE, Mass., April 11, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•23 days ago
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy
Preclinical data presented at the American Association for Cancer Research annual meeting provide further support for the potential of SRK-181 to overcome primary resistance to.
- GlobeNewswire•last month
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the.
- GlobeNewswire•last month
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
Selective inhibition of TGFβ1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism.
- GlobeNewswire•2 months ago
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 06, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•2 months ago
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA)Pharmacodynamic Results Demonstrate Robust.
- Zacks•2 months ago
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
- Simply Wall St.•4 months ago
Read This Before Selling Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Investopedia•4 months ago
Gilead Stock Breaks Out to Channel Resistance
Gilead Sciences shares posted gains on Thursday morning after Bistrol-Myers' acquisition of Celgene sent shares across the sector higher.
- GlobeNewswire•4 months ago
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- Motley Fool•4 months ago
Why Cabot Oil & Gas, Uxin, and Scholar Rock Holding Slumped Today
Several stocks simply lost momentum from past successes.
- Zacks•4 months ago
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
- Zacks•4 months ago
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
- Benzinga•4 months ago
Raymond James: Gilead In NASH For The Long Haul
Gilead Sciences, Inc. (NASDAQ: GILD ) announced a strategic collaboration Wednesday with Scholar Rock Holding Corp (NASDAQ: SRRK ). Although not strictly a nonalcoholic steatohepatitis, or NASH, deal, ...
- Business Wire•4 months ago
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
Gilead Sciences, Inc. (GILD) and Scholar Rock Holding Corporation (SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be responsible for the program’s preclinical and clinical development and commercialization.
- GlobeNewswire•5 months ago
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending SRK-015 (human anti-promyostatin monoclonal antibody) for designation as an orphan medicinal product for the treatment of Spinal Muscular Atrophy (SMA). SRK-015 was previously granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in March 2018. Orphan Medicinal Product Designation by the European Commission is available to companies developing products intended to treat a life-threatening or chronically debilitating condition that affects fewer than five in 10,000 people in the EU, and has the potential to be of significant benefit. This designation could allow for a number of incentives, including protocol assistance, access to the centralized authorization procedure, reduced regulatory fees, and a 10-year period of marketing exclusivity in the EU after product approval.
- GlobeNewswire•5 months ago
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass., Nov. 29, 2018 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•5 months ago
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
CAMBRIDGE, Mass., Nov. 27, 2018 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•5 months ago
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Edward (Ted) Myles, a financial and operational leader with deep experience across the biotechnology and pharmaceutical industries, has been appointed to the Company’s Board of Directors. Mr. Myles will serve as chair of the Company’s audit committee and as a member of the compensation committee.
- GlobeNewswire•5 months ago
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, Renders Resistant Solid Tumors.
- GlobeNewswire•6 months ago
Scholar Rock to Present at the Jefferies 2018 London Healthcare Conference
Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 4:40 p.m. GMT / 11:40 a.m. EST. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
